Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
Boehringer Ingelheim
Colorcon
McKesson
Express Scripts
Harvard Business School

Last Updated: June 27, 2022

PHOTREXA Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

Which patents cover Photrexa, and what generic alternatives are available?

Photrexa is a drug marketed by Glaukos and is included in one NDA.

The generic ingredient in PHOTREXA is riboflavin 5'-phosphate sodium. There are ten drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the riboflavin 5'-phosphate sodium profile page.

Drug patent expirations by year for PHOTREXA
DrugPatentWatch® Estimated Generic Entry Opportunity Date for PHOTREXA
Generic Entry Date for PHOTREXA*:
Constraining patent/regulatory exclusivity:
TREATMENT OF CORNEAL ECTASIA FOLLOWING REFRACTIVE SURGERY
NDA:
Dosage:
SOLUTION/DROPS;OPHTHALMIC

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for PHOTREXA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Avedro, Inc.Phase 4
Comprehensive EyeCare of Central OhioPhase 4
Glaukos CorporationPhase 4

See all PHOTREXA clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for PHOTREXA

US Patents and Regulatory Information for PHOTREXA

PHOTREXA is protected by zero US patents and two FDA Regulatory Exclusivities.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of PHOTREXA is See Plans and Pricing.

This potential generic entry date is based on TREATMENT OF CORNEAL ECTASIA FOLLOWING REFRACTIVE SURGERY.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

FDA Regulatory Exclusivity protecting PHOTREXA

TREATMENT OF CORNEAL ECTASIA FOLLOWING REFRACTIVE SURGERY
Exclusivity Expiration: See Plans and Pricing

TREATMENT OF PROGRESSIVE KERATOCONUS
Exclusivity Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaukos PHOTREXA riboflavin 5'-phosphate sodium SOLUTION/DROPS;OPHTHALMIC 203324-001 Apr 15, 2016 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Glaukos PHOTREXA VISCOUS IN DEXTRAN 20% riboflavin 5'-phosphate sodium SOLUTION/DROPS;OPHTHALMIC 203324-002 Apr 15, 2016 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Glaukos PHOTREXA riboflavin 5'-phosphate sodium SOLUTION/DROPS;OPHTHALMIC 203324-001 Apr 15, 2016 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Glaukos PHOTREXA VISCOUS IN DEXTRAN 20% riboflavin 5'-phosphate sodium SOLUTION/DROPS;OPHTHALMIC 203324-002 Apr 15, 2016 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Baxter
Mallinckrodt
McKesson
Medtronic
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.